Genetic Determinants of Clinical Phenotype in Hypertrophic Cardiomyopathy

Lazar Velicki (lvelicki@gmail.com)
Institute of cardiovascular diseases Vojvodina  https://orcid.org/0000-0002-2907-819X

Djordje G Jakovljevic
Newcastle Upon Tyne Hospitals NHS Foundation Trust

Andrej Preveden
Institute of cardiovascular diseases Vojvodina

Miodrag Golubovic
Institut za onkologiju Vojvodine Klinika za internu onkologiju

Marija Bjelobrk
Institut za onkologiju Vojvodine Klinika za internu onkologiju

Aleksandra Illic
Institut za onkologiju Vojvodine Klinika za internu onkologiju

Snezana Stojsic
Institut za onkologiju Vojvodine Klinika za internu onkologiju

Fausto Barlocco
Universita degli Studi di Firenze

Maria Tafelmeier
Universitätsklinikum Regensburg Klinik und Poliklinik Innere Medizin II

Nduka Okwose
Newcastle Upon Tyne Hospitals NHS Foundation Trust

Milorad Tesic
Medicinski fakultet Univerzitet u Beogradu

Paul Brennan
Newcastle Upon Tyne Hospitals NHS Foundation Trust

Dejana Popovic
Medicinski fakultet Univerzitet u Beogradu

Arsen Ristic
Medicinski fakultet Univerzitet u Beogradu

Guy A MacGowan
Newcastle Upon Tyne Hospitals NHS Foundation Trust

Nenad Filipovic
Univeristy of Kragujevac

Lars S. Maier
Research article

Keywords: Hypertrophic Cardiomyopathy, Clinical Phenotype

DOI: https://doi.org/10.21203/rs.3.rs-36810/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease that affects approximately one in 500 people. HCM is a recognized genetic disorder most often caused by mutations involving myosin-binding protein C (MYBPC3) and β-myosin heavy chain (MYH7) which are responsible for approximately three-quarters of the identified mutations.

Methods: As a part of the international multidisciplinary SILICOFCM project (www.silicofcm.eu) the present study evaluated the association between underlying genetic mutations and clinical phenotype in patients with HCM. Only patients with confirmed single pathogenic mutations in either MYBPC3 or MYH7 genes were included in the study and divided into two groups accordingly. The MYBPC3 group was comprised of 48 patients (76%), while the MYH7 group included 15 patients (24%). Each patient underwent clinical examination and echocardiography.

Results: The most prevalent symptom in patients with MYBPC3 was dyspnea (44%), whereas in patients with MYH7 it was palpitations (33%). The MYBPC3 group had a significantly higher number of patients with a positive family history of HCM (46% vs. 7%; p=0.014). There was a numerically higher prevalence of atrial fibrillation in the MYH7 group (60% vs. 35%, p=0.085). Laboratory analyses revealed normal levels of creatinine (85.5±18.3 vs. 81.3±16.4 µmol/l; p=0.487) and blood urea nitrogen (10.2±15.6 vs. 6.9±3.9 mmol/l; p=0.472) which were similar in both groups. The systolic anterior motion presence was significantly more frequent in patients caring MYH7 mutation (33% vs. 10%; p=0.025), as well as mitral leaflet abnormalities (40% vs. 19%; p=0.039). Calcifications of mitral annulus were registered only in MYH7 patients (20% vs. 0%; p=0.001). The difference in diastolic function, i.e. E/e' ratio between the two groups was also noted (MYBPC3 8.8±3.3, MYH7 13.9±6.9, p=0.079).

Conclusions: Major findings of the present study corroborate the notion that MYH7 gene mutation patients are presented with more pronounced disease severity than those with MYBPC3.

Background

Hypertrophic cardiomyopathy (HCM) is the most frequent inherited disease of the myocardium, with a prevalence of approximately 0.2% [1, 2]. Despite the significant developments in diagnostic tools and genetic tests, the diagnosis of HCM is often delayed [2].

HCM is characterized by left ventricular (LV) hypertrophy without dilatation, in the absence of any other cardiac, systemic, metabolic, or syndromic disease that could explain myocardial hypertrophy [2-5]. Clinical presentation of HCM varies from completely asymptomatic with normal life expectancy, to typical symptoms like chest pain, shortness of breath, heart failure, palpitations, syncope, and in the worst case even sudden cardiac death [2, 6]. Complications of non-obstructive HCM include advanced myocardial fibrosis, microvascular ischemia, and deterioration of cardiac function [7].
HCM is recognized genetic disorder transmitted in an autosomal dominant fashion, caused by a single mutation in one of the sarcomeric protein genes, which can be present in either thick- or thin-filament genes [8, 9]. The two most common mutations involving thick filament are myosin-binding protein C (MYBPC3) and β-myosin heavy chain (MYH7) gene mutations, which are responsible for approximately three-quarters of the identified mutations in HCM patients [9, 10]. Aside from these two, a few other less frequent gene mutations (e.g. troponin I type 3 [TNNI3], troponin T type 2 [TNNT2], α-tropomyosin [TPM1], α-actin [ACTC]) are possible causes of HCM as well and are therefore also included in the routine HCM genetic testing [11]. Technological progress has made it possible to identify new genes associated with HCM - numerous other genes that do not encode sarcomere proteins but rather genes encoding the synthesis of Z-disk proteins and proteins involved in the calcium signaling pathway. With the introduction and implementation of the next-generation sequencing solutions, the identification of nearly 50 gene mutations associated with some form of HCM throughout literature has become possible [12].

Regardless of the mutation type, the same pathophysiology mechanisms are responsible for the development of typical HCM phenotype and disease progression. Disrupted sarcomere properties due to the mutations cause impaired relaxation and lead to diastolic dysfunction, which is followed by hyperdynamic contractility and hypertrophy of the LV in the later course [9, 11].

Due to variable penetrance and expressivity, the phenotypic characteristics of HCM are multifaceted and may be influenced by other factors beyond single pathogenic mutations [13]. In addition to LV hypertrophy, phenotypic HCM expression also includes myocardial hypercontractivity, myofibril disorganization, fibrosis, as well as the presence of mild myocardial inflammation. Although the clinical phenotype can partially differ depending on the affected gene, no distinctive correlation between disease severity and specific genes has been established. Moreover, clinical features such as disease penetration, hypertrophy severity, and patient prognosis are known to vary depending on different mutations within the same gene [11].

The precise link between determined underlying gene mutation and the clinical course remains elusive in this heterogeneous condition. The motivation to compile this HCM patient registry was to try to define what patient features are more prevalent with specific gene mutations and to establish whether the level of disease expression might be linked to one of the two most common mutations responsible for HCM. The goal was to reveal and distinguish subtle differences that may exist in clinical presentation and, more importantly, in heart structure and function recorded by cardiac imaging (i.e. echocardiography) between different gene mutations, thus providing essential information for the computational model development. Moreover, data from this study will also complement the clinical trial (NCT03832660 at clinicaltrials.gov) evaluating the effects of pharmacological (sacubitril/valsartan) versus lifestyle intervention in HCM patients [14], also a fundamental part of the SILICOFCM project.

Methods
As a part of the international multidisciplinary SILICOFCM project (www.silicofcm.eu) developing a computational platform for in silico clinical trials of familial cardiomyopathies, the present study evaluated the association between genetic mutations and clinical phenotype in patients with HCM. The study protocol was approved by the UK National Health Service Health Research Authority North East – Tyne & Wear South Research Ethics Committee with the reference number 18/NE/0318 and was adopted by the Institutional Review Board of each participating center. All patients provided written informed consent and all procedures were conducted following the Declaration of Helsinki.

**Study design**

Participating centers included patients with diagnoses of HCM who were identified in the period from June 2018 to February 2019.

The diagnosis of HCM was defined according to the European Society of Cardiology guidelines i.e. maximal LV wall thickness of ≥15 mm on echocardiography, in the absence of any other cardiac or systemic disease that would be capable of producing myocardial hypertrophy, such as afterload abnormalities like aortic valve stenosis or arterial hypertension [5]. Of the total of 74 HCM patients, 11 were excluded because the relatively small number of other gene mutations (TNNI3 – 5 patients, TNNT2 – 2 patients, TPM1 – 1 patient, myosin heavy chain 6 – 1 patient, myosin light chain 2 – 1 patient, lamin A/C – 1 patient) might have biased the overall study analysis. In the final analysis, the study included a total of 63 adult patients with a confirmed diagnosis of HCM.

We excluded patients with significant atherosclerotic coronary artery disease (>50% stenosis in a major artery), patients with prior cardiac surgery (including septal myectomy), alcohol septal ablation, major LV outflow obstruction with pressure gradient >50 mmHg, and chronic renal failure (<30 ml/min/1.73 m²).

**Genetic testing**

Genetic testing was performed from peripheral blood samples acquired by phlebotomy with the utilization of the QIAamp DNA Blood BioRobot MDx kit (QIAGEN GmbH, Hilden, Germany). Polymerase chain reaction with primers was used for the amplification of candidate exons.

Blood samples were analyzed for the presence of the 8 most common mutations, which represent the basis of the commonly available genetic tests for HCM. These mutations include the protein-coding exons responsible for encoding myosin-binding protein C (MYBPC3), thick-filament proteins (β-myosin heavy chain [MYH7] and the regulatory and essential light chains [MYL2 and MYL3]), and thin-filament proteins (troponin T type 2 [TNNT2], troponin I type 3 [TNNI3], α-tropomyosin [TPM1], and α-actin [ACTC]).

Only patients with confirmed single pathogenic mutations in either MYBPC3 or MYH7 genes were included in the study. Based on the identified gene mutation the patients were divided into two groups. The MYBPC3 group was comprised of 48 patients (76%), while the MYH7 group included 15 patients (24%).
**Echocardiography**

Transthoracic echocardiography was performed in all patients. Images were acquired from standard parasternal and apical views, with simultaneous ECG monitoring. All the parameters were calculated for the body surface area (BSA).

LV wall thickness and chamber dimensions were measured in the parasternal long-axis view [14, 15]. LV myocardial mass was calculated using the Devereux formula [16] and then normalized for BSA.

Relative wall thickness was calculated as two times the LV posterior wall thickness divided by LV end-diastolic diameter.

LV systolic and diastolic volumes and ejection fraction were calculated from Simpson’s modified biplane method from the apical 4-chamber and 2-chamber views [15].

Diastolic function was evaluated in the apical 4-chamber view [17]. Transmittal inflow was recorded using pulsed-wave Doppler at the tips of mitral valve leaflets. The peak velocity of the early diastolic filling (E), was measured. Early (e’s and e’l) and late (a’s and a’l) velocities of septal end lateral mitral annulus were measured using TDI and then their average ratio e’/a’av was calculated.

Numerous studies have shown that the E/e’, a volume independent parameter, represents the most accurate index of the LV filling pressure [18]. It was calculated as the average ratio between E/e’s and E/e’l as E/e’av.

**Statistical analysis**

Statistical analysis was performed using the SPSS 20.0 (Statistical Package for Social Science for Windows 17). A p-value of <0.05 was considered statistically significant. The Kolmogorov–Smirnov test was used for the determination of quantitative data distribution. Differences of mean values were tested by the independent samples-test or Mann-Whitney U test and results are presented as mean (standard deviation) or median (25th to 75th percentile). The relations between categorical variables were tested using the chi-square ($\chi^2$) test and the results are presented as frequencies and percentages.

**Results**

The mean age of HCM patients regardless of genetic mutation was 51.1±14.2 years and most of them were male 48 (76%). They were slightly overweight according to their mean BMI of 26.4±4.4 kg/m$^2$. One-third of patients (36%) had a positive family history for HCM.

Differences in terms of patient profile depending on genetic mutation are shown in Table 1.

There was no significant difference between patients carrying the MYBPC3 and MYH7 mutations regarding age (49.8±14.3 vs. 55.1±13.3 years, p=0.211) and gender distribution (21% vs. 33% females,
The most prevalent symptom in patients with MYBPC3 was dyspnea (44%), whereas in patients with MYH7 it was palpitations (33%). Other less frequently reported symptoms included fatigue, chest pain, and syncope, with similar distribution among the groups.

Interestingly, the MYBPC3 group had a significantly higher number of patients with a positive family history of HCM (46% vs. 7%; p=0.014).

**Table 1** General characteristics of patients with MYBPC3 and MYH7 gene mutation
|                                | Overall     | MYBPC3     | MYH7       | p-value |
|--------------------------------|-------------|------------|------------|---------|
| Age (years)                    | 51.1±14.2   | 49.8±14.3  | 55.1±13.3  | 0.211   |
| Females, n (%)                 | 15 (23.8%)  | 10 (20.8%) | 5 (33.3%)  | 0.321   |
| BMI (kg/m²)                    | 26.4±4.4    | 26.1±4.6   | 27.8±3.1   | 0.260   |
| Fatigue, n (%)                 | 9 (14.3%)   | 7 (14.6%)  | 2 (13.3%)  | 0.881   |
| Dyspnea, n (%)                 | 25 (39.7%)  | 21 (43.7%) | 4 (26.7%)  | 0.238   |
| Chest pain, n (%)              | 6 (9.5%)    | 4 (8.3%)   | 2 (13.3%)  | 0.565   |
| Palpitations, n (%)            | 13 (20.6%)  | 8 (16.7%)  | 5 (33.3%)  | 0.177   |
| Syncope, n (%)                 | 10 (15.9%)  | 9 (18.7%)  | 1 (6.6%)   | 0.264   |
| Family history of HCM, n (%)   | 23 (36.5%)  | 22 (45.8%) | 1 (6.6%)   | 0.014*  |
| Comorbidities                  |             |            |            |         |
| Diabetes mellitus, n (%)       | 3 (4.8%)    | 3 (6.2%)   | -          | -       |
| Chronic obstructive pulmonary disease, n (%) | 2 (3.2%) | 2 (4.2%) | -          | -       |
| Thyroid dysfunction, n (%)     | 8 (12.7%)   | 7 (14.6%)  | 1 (6.7%)   | 0.422   |
| Anemia, n (%)                  | 1 (1.6%)    | 1 (2.1%)   | -          | -       |
| Laboratory analyses            |             |            |            |         |
| Glucose (mmol/l)               | 5.6±1.2     | 5.8±1.3    | 5.0±0.6    | 0.071   |
| Creatinine (µmol/l)            | 84.4±17.7   | 85.5±18.3  | 81.3±16.4  | 0.487   |
| Blood urea nitrogen (mmol/l)   | 9.0±12.7    | 10.2±15.6  | 6.9±3.9    | 0.472   |
| ALT (U/l)                      | 30.1±15.7   | 31.8±17.0  | 25.0±10.4  | 0.268   |
| Total protein (g/l)            | 69.1±8.4    | 69.3±7.2   | 68.6±11.1  | 0.853   |
| Albumin (g/l)                  | 44.0±6.8    | 44.1±6.4   | 43.9±8.0   | 0.948   |
| Sodium (mmol/l)                | 140.3±2.1   | 140.4±2.1  | 140.2±2.3  | 0.868   |
| Potassium (mmol/l)             | 4.5±0.4     | 4.5±0.3    | 4.6±0.5    | 0.531   |
| Calcium (mmol/l)               | 2.3±0.1     | 2.3±0.1    | 2.3±0.2    | 0.689   |
| NT-proBNP (ng/l)               | 1328.3±1420.2 | 1304.5±1457.5 | 1757.2±1335.2 | 0.766   |

*Abbreviations: ALT alanine transaminase; BMI body mass index, HCM hypertrophic cardiomyopathy; NT-proBNP N-terminal pro-brain natriuretic peptide*
The most frequently found comorbidity was thyroid gland dysfunction, which was present in 8 patients (13%) in total, without significant difference between MYBPC3 and MYH7 groups (15% vs. 7%; p=0.422). No significant difference between the MYBPC3 and MYH7 patients was observed in other comorbidities as well: diabetes mellitus (6% vs. 0%; p=0.321), chronic obstructive pulmonary disease (4% vs. 0%; p=0.422), anemia (2% vs. 0%; p=0.573).

The mean heart rate was similar between MYBPC3 and MYH7 patients (64.6±11.8 vs. 67.8±20.4 bpm; p=0.546). However, there was a numerically higher prevalence of atrial fibrillation in the MYH7 group (60% vs. 35%, p=0.085).

Blood laboratory analyses indicating renal and liver function, as well as blood glucose and electrolytes showed levels within the reference range, without differences between MYBPC3 and MYH7 patients (Table 1). Levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) were elevated in all patients, but without difference among groups.

Echocardiography findings are presented in Table 2 and Figure 1. There was no difference in the posterolateral wall (10.6±2.1 vs. 10.8±1.7 mm, p=0.776) and interventricular septum (21.5±7.0 vs. 21.6±7.9 mm, p=0.982) thickness between MYBPC3 and MYH7 patients. Left atrial volume was 14% lower (p=0.518) and left ventricular end-diastolic volume was 19% higher (p=0.560) in MYBPC3. Left ventricular end-systolic volume was similar between MYBPC3 and MYH7 (52.6±37.4 vs. 44.0±19.0 ml; p=0.700) as was left ventricular ejection fraction (55.6±8.2 vs. 54.1±6.3, p=0.594) and tricuspid annular plane systolic excursion (TAPSE) (21.0±4.4 vs. 22.5±6.0 mm, p=0.363).

Importantly, the systolic anterior motion was significantly higher in patients caring MYH7 mutation (33% vs. 10%; p=0.025), as well as mitral leaflet abnormalities (40% vs. 19%; p=0.039). Calcifications of mitral annulus were registered only in MYH7 patients (20% vs. 0%; p=0.001).

An interesting finding is the difference of E/e' ratio – a marker of LV filling pressure – between the groups (MYBPC3 8.8±3.3, MYH7 13.9±6.9, p=0.079). Although the level of significance is slightly beyond the threshold, the difference is indicative.

**Table 2** Echocardiography findings in patients with MYBPC3 and MYH7 gene mutation
|                                | Overall    | MYBPC3    | MYH7      | p-value |
|--------------------------------|------------|-----------|-----------|---------|
| PLW thickness (mm)             | 10.6±2.0   | 10.6±2.1  | 10.8±1.7  | 0.776   |
| IVS thickness (mm)             | 21.5±7.1   | 21.5±7.0  | 21.6±7.9  | 0.982   |
| LA volume (ml)                 | 115.6±56   | 111.7±83.9| 130.3±87.2| 0.518   |
| LV end-diastolic volume (ml)   | 108.9±49.7 | 110.8±52.2| 92.7±7.0  | 0.560   |
| LV end-systolic volume (ml)    | 51.6±35.6  | 52.6±37.4 | 44.0±19.0 | 0.700   |
| LV ejection fraction (%)       | 55.3±7.8   | 55.6±8.2  | 54.1±6.3  | 0.594   |
| LV mass (g)                    | 301.4±114.0| 306.0±115.2| 261.0±115.4| 0.527   |
| LV mass index (g/m²)           | 155.9±52.3 | 159.0±53.1| 129.5±43.1| 0.364   |
| Relative wall thickness        | 0.43±0.10  | 0.44±0.10 | 0.34±0.02 | 0.103   |
| LV outflow pressure gradient (mmHg) | 8.2±11.1   | 6.0±2.5   | 16.1±22.7 | 0.252   |
| E/e' ratio                     | 9.7±4.5    | 8.8±3.3   | 13.9±6.9  | 0.079*  |
| TAPSE (mm)                     | 21.4±4.8   | 21.0±4.4  | 22.5±6.0  | 0.363   |
| Systolic anterior motion, n (%)| 10 (15.9%) | 5 (10.4%) | 5 (33.3%) | 0.025*  |
| Papillary muscle abnormalities, n (%) | 4 (6.3%)   | 4 (8.3%)  | -         | 0.261   |
| Mitral leaflet abnormalities, n (%) | 15 (23.8%) | 9 (18.8%) | 6 (40.0%) | 0.039*  |
| Calcification of mitral annulus, n (%) | 3 (4.8%)   | -         | 3 (20.0%) | 0.001*  |

Abbreviations: PLW posterolateral wall, IVS interventricular septum, LA left atrium, LV left ventricle, E/e' LV filling pressure, TAPSE tricuspid annular plane systolic excursion

**Discussion**

The genetic basis of HCM is more complex than previously thought: known genetic mutations are responsible for about half of the cases, while the remaining causes are unknown. Since variants have not been found to explain the presence of the disease in many patients, there are certainly other, yet unidentified genes. There is an emphasized need to discover additional genetic, epigenetic, and environmental causes that would explain the high proportion of cases of unknown etiology. For many newly reported genes, the lack of strong evidence to support a causal role in HCM creates uncertainty in the interpretation of the results. One of the major roles of genetic testing for HCM patients is better clinical surveillance of asymptomatic family members.

This study analyzed the genetic determinacy of various clinical phenotype parameters among patients with HCM. Only carriers of a single gene mutation, either MYBPC3 or MYH7 were included. Studies that performed genetic screening in large cohorts of patients with a confirmed clinical diagnosis of HCM
managed to detect a pathogenic mutation in about 40-50% of patients [13, 15], suggesting that as much as half of the HCM diagnosed patients do not have known sarcomeric gene mutations.

The MYBPC3 and MYH7 mutations are the two most common mutations among HCM patients with identified sarcomeric gene mutations. A recent meta-analysis on 7675 HCM patients including a total of 51 studies performed by Sedaghat-Hamedani et al. [16] found that the prevalence of MYBPC3 and MYH7 gene mutations were 20% and 14%, respectively, while all the other mutations had a prevalence below 2%.

HCM is a disease of a younger age, as it is often first diagnosed before the age of 40 [15, 17]. In our study, patients’ mean age was 50 for MYBPC3 and 55 for MYH7 mutations, with no significant difference among groups. This is in contrast to previous findings, which suggest earlier onset and diagnosis of the disease for MYH7 mutation [16, 18]. Patients in our study were predominantly male, which is consistent with gender distribution across literature, where about two-thirds of HCM patients are male [13, 19, 20].

Olivotto et al. [21] in their study from 2005, examined gender-related differences in a multicenter population of 969 patients with HCM. Male patients had a 3:2 predominance (59%). HCM-related mortality and risk of sudden death were similar in men and women. They also pointed out that women with HCM were under-represented, older, and more symptomatic than men, and showed a higher risk of progression to advanced heart failure or death, often associated with outflow obstruction. Results from a more recent study from Jang et al. [22] conducted on 202 consecutive patients with non-obstructive HCM are in-line with previously mentioned. Jang et al. concluded that female patients presented with heart failure more frequently and showed a higher risk of cardiovascular events than male patients. LA volume, E/e’ and LV mechanics were different between the genders, suggesting that these might contribute to greater susceptibility to heart failure in women with HCM.

Patients with MYBPC3 mutation in our study had a notable number (46%) of relatives with a confirmed HCM diagnosis. Across the literature, various rates of positive family history ranging from 25-70% have been reported [18, 19]. However, the reliability of these numbers should be taken with reserve, because family screening in patients with HCM has still not been fully implemented, despite the clear recommendations for a detailed follow-up of all adult first-degree relatives [5, 23]. New evidence suggests that screening should be performed even earlier in child age, especially in families with MYBPC3 and MYH7 mutations [24]. Moreover, the diagnosis in relatives is often established solely on phenotypic expression (i.e. imaging methods like echocardiography and cardiac magnetic resonance), without proper genetic testing. Even in the case of performed genetic analysis, currently available methods still fail to identify more than half of patients with HCM [25].

Several studies have attempted to differentiate between disease severity, progression, and phenotype-based on specific mutation subclasses, but there is currently no consensus as to whether a specific phenotype or prognosis can be predicted from an MYBPC3 mutation [26]. Mutation of the MYH7 gene is associated with an earlier onset of symptoms, more pronounced hypertrophy, and poor prognosis [27]. The Arg453Cys mutation of MYH7 is associated with a high incidence of terminal heart failure and premature death [28]. Several studies have found a correlation between five mutations (four in the MYH7
gene and one in the gene encoding cardiac troponin T) and high incidences of advanced cardiac death, however, these associations were not consistent with the results of other studies [29].

The study by Olivotto et al. [30] assessed the occurrence of atrial fibrillation and outcome in 480 consecutive HCM patients (age at diagnosis, 45±20 years; 61% male) during a follow-up period of 9.1±6.4 years. In their cohort, atrial fibrillation was documented in 107 patients, with a prevalence of 22%. Authors concluded that atrial fibrillation is associated with substantial risk for heart failure-related mortality, stroke, and severe functional disability, particularly in patients with outflow obstruction, those ≤ 50 years of age, or those developing chronic atrial fibrillation.

Atrial fibrillation tended to be more prevalent in the MYH7 group in our study. This finding is consistent with previous studies [17, 31], which reported a higher incidence of atrial fibrillation in patients with MYH7 mutation in comparison to other HCM patients. Since the development of atrial fibrillation was associated with risk factors such as LA enlargement, LV wall thickness, and LV outflow tract obstruction, these results suggest that patients with MYH7 mutation present with a more severe clinical phenotype. However, a prospective study on 237 HCM patients with a mean follow-up period of 14±10 years found no statistically significant difference in atrial fibrillation between patients with MYBPC3 and MYH7 mutations, with an incidence of 31% and 37%, respectively [32].

Detailed analysis of echocardiography parameters between the MYBPC3 and MYH7 groups in the present study revealed a somewhat similar phenotype expression with minor differences between the groups, although with slightly more severe disease presentation in MYH7 group. Most importantly, LV wall hypertrophy was equally expressed in both groups at the posterolateral wall and interventricular septum. Previous studies on larger groups of HCM patients that analyzed myocardial wall thickness measured by both echocardiography [16-18, 33] and cardiac magnetic resonance [20] also discovered no significant differences regarding LV wall thickness between MYBPC3 and MYH7 patients. The somewhat counterintuitive finding came from the Florence group [34], stating that LV mass index was normal in about 20% of patients with definite HCM phenotype and that increased LV mass alone should not be the parameter for establishing the clinical diagnosis of HCM. The LV mass correlated weakly with maximal wall thickness and proved more sensitive in predicting outcomes.

Heart systolic function measured through ejection fraction for LV and TAPSE for right ventricle were preserved in all study patients, with no differences between the groups. This is consistent with previous findings and current standpoint that HCM generally does not lead to systolic function deterioration. The symptoms and clinical severity are dominantly determined by the combination of diastolic dysfunction, mitral apparatus abnormalities, and LV outflow tract obstruction [35, 36]. A recent study by Miller et al. [37] established that patients with pathogenic, likely pathogenic or rare MYH7 variants had higher LV ejection fraction than those with MYBPC3 variants (68.8 vs. 59.1, p<0.001) and higher right ventricle ejection fraction (67.3 vs. 60.8, p = 0.018). Additionally, patients with MYBPC3 variants were more likely to have LV ejection fraction <55% (29.7% vs. 4.9%, p = 0.005).
Very interesting paper from Maron et al. [38] looked at whether morphological abnormalities of the mitral valve represent part of the HCM disease process. Assessment of mitral valve morphology was performed using cardiovascular magnetic resonance in 172 HCM patients (age 42±18 years; 62% men) and 172 control subjects. After careful characterization, they concluded that mitral valve leaflets are elongated independently of other disease variables, likely constituting a primary phenotypic expression of this heterogeneous disease and are an important morphological abnormality responsible for LV outflow obstruction. We wanted to further classify mitral valve abnormalities depending on the genetic basis. In this regard, the MYH7 group in our study had a significantly higher number of mitral leaflet abnormalities, mitral annulus calcifications, and the most important higher number of systolic anterior motion, contributing to the worse phenotype expression of MYH7 versus MYBPC3 gene mutations. The study of Groarke et al. [39] observed an increased number of mitral valve abnormalities in patients with sarcomeric gene mutations, however, they did not analyze the difference among the particular gene mutations. Waldmüller et al. [15] on the other hand, reported a more severe level of mitral regurgitation in patients with MYH7 mutation than in patients with MYBPC3 mutation.

Diagnosis of hereditary cardiac disorders based on genetic information is particularly challenging because of the high genetic heterogeneity and overlapping and variable nature of these clinical presentations. The clinical presentation of HCM is influenced by age, lifestyle, and presence of hypertension, among other factors. Although there is still no consensus on the exact impact of gender on HCM presentation and progression, gender influence is thought to exist and that differences in gene expression and hormonal differences affect the symptoms and clinical outcomes of HCM.

Our study was able to demonstrate the subtle but clinically important difference between patients with different genetic profiles. The clinical implications that may arise from these findings point to the fact that structural abnormalities are more prevalent in MYH7 gene mutation. Patients with MYH7 mutation would probably benefit from more intense imaging surveillance that should start at a younger age as they are likely to develop mitral valve dysfunction and LVOT obstruction. Concerning diastolic dysfunction, it is reasonable to assume that patients with MYH7 gene mutation would benefit from earlier commencement and more aggressive medical treatment. Given the clinical profile, MYH7 mutation patients would be ideal candidates for cardiac myosin inhibitors such as mavacamten. Strenuous exercise should be routinely discouraged, especially in patients with the MYH7 gene mutation.

Our data also suggest and confirm already established management paradigms – an individualized approach concerning specific underlying clinical conditions and pathways (sudden cardiac death risk, heart failure, and atrial fibrillation). Such an approach has been proven to provide the opportunity to aggressively alter the progression of the disease, prevent mortality, and provide normal or extended life expectancy associated with improved quality of life.

**Study limitations**

We acknowledge that the large number of operators involved in echocardiographic measurements in this multicenter study represents an unavoidable limitation. However, care was taken to standardize
measurements of cardiac dimension and function by prospectively providing detailed technical instructions to all participating centers.

Finally, although the number of included patients in the study is modest, we believe that patient heterogeneity (multicenter study) confers substantial power to our data. Nevertheless, the modest size is one reason to exercise caution in extrapolating these results to the broad spectrum of hypertrophic cardiomyopathy.

Cross-sectional study design does not allow monitoring of disease progression. However, disease progression and response to pharmacological and lifestyle intervention in HCM is subject to our separate ongoing longitudinal SILICOFCM study [14].

Conclusions

Up to this point, numerous mutations leading to HCM have been identified and various clinical manifestations and phenotypic expressions of HCM have been described (from a completely asymptomatic condition, through outflow tract obstruction, diastolic dysfunction, to progressive heart failure and sudden cardiac death). However, no consistent association between the HCM genotype and phenotype have been identified.

In those terms, our study is no exception. Although we focused our attention on the two most common sarcomeric gene mutations responsible for HCM – MYBPC3 and MYH7 gene mutations – we were not able to demonstrate any substantial differences regarding clinical and echocardiography findings. More frequent systolic anterior motion and other mitral valve abnormalities as well as increased left ventricle filling pressure in MYH7 gene mutation suggests that MYH7 gene mutation does present with a more severe disease phenotype.

Abbreviations

ACTC: α-actin; BMI: body mass index; BSA: body surface area; CO: cardiac output; E/e': left ventricle filling pressure; HCM: hypertrophic cardiomyopathy; HR: heart rate; IVS: interventricular septum; LA: left atrium; LV: left ventricle; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricle end-systolic volume; LVmass: left ventricle myocardial mass; MYBPC3: myosin-binding protein C; MYH7: β-myosin heavy chain; PLW: posterolateral wall; RWT: relative wall thickness; SV: stroke volume; TAPSE: tricuspid annular plane systolic excursion; TNNI3: troponin I type 3; TNNT2: troponin T type 2; TPM1: α-tropomyosin.

Declarations

Ethics approval and consent to participate

The study was approved by the UK National Health Service Health Research Authority North East – Tyne & Wear South Research Ethics Committee with reference number 18/NE/0318 and adopted by the
Institutional Review Board of each participating institution with study participants providing informed consent.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work has been conducted as part of the SILICOFCM project which received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No 777204. The funder did not influence data collection or interpretation.

**Authors’ contributions**

LV, DGJ, LM, and IO conceptualized and designed the study. LV and AP analyzed and interpreted the data, and wrote the manuscript. LV, DGJ, AR, GAM, LM, and IO revised the manuscript. AP, MG, MB, AI, SS, FB, MT, NO, MT, PB, NF and DP participated in data acquisition and database creation. All authors approved the final version of the manuscript.

**Acknowledgments**

Not applicable.

**References**

1. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242-55.
2. Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. The New England journal of medicine. 2018;379(20):1977.
3. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761-96.
4. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. Journal of the
American College of Cardiology. 2014;64(1):83-99.

5. Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European heart journal. 2014;35(39):2733-79.

6. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. 2010;122(11):1130-3.

7. Lu DY, Pozios I, Haileselassie B, Ventoulis I, Liu H, Sorensen LL, et al. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 2018;7(5).

8. Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99(24):1800-11.

9. Garfinkel AC, Seidman JG, Seidman CE. Genetic Pathogenesis of Hypertrophic and Dilated Cardiomyopathy. Heart failure clinics. 2018;14(2):139-46.

10. Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clinic proceedings. 2008;83(6):630-8.

11. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nature clinical practice Cardiovascular medicine. 2008;5(3):158-68.

12. Mazzarotto F, Girolami F, Boschi B, Barlocco F, Tomberli A, Baldini K, et al. Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. Genetics in medicine : official journal of the American College of Medical Genetics. 2019;21(2):284-92.

13. Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. European journal of medical genetics. 2010;53(5):261-7.

14. Tafelmeier M, Baessler A, Wagner S, Unsoeld B, Preveden A, Barlocco F, et al. Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. Clinical cardiology. 2020.

15. Waldmuller S, Erdmann J, Binner P, Gelbrich G, Pankuweit S, Geier C, et al. Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure. European journal of heart failure. 2011;13(11):1185-92.

16. Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, Lai A, Amr A, Haas J, et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clinical research in cardiology : official journal of the German Cardiac Society. 2018;107(1):30-41.
17. Marsiglia JD, Credidio FL, de Oliveira TG, Reis RF, Antunes Mde O, de Araujo AQ, et al. Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy. American heart journal. 2013;166(4):775-82.

18. Garcia-Castro M, Coto E, Reguero JR, Berrazueta JR, Alvarez V, Alonso B, et al. [Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy]. Rev Esp Cardiol. 2009;62(1):48-56.

19. Liu X, Jiang T, Piao C, Li X, Guo J, Zheng S, et al. Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing. Scientific reports. 2015;5:11411.

20. Weissler-Snir A, Hindieh W, Gruner C, Fourey D, Appelbaum E, Rowin E, et al. Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (beta-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy. Circulation Cardiovascular imaging. 2017;10(2).

21. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2005;46(3):480-7.

22. Jang JH, Shin SH, Beak YS, Ko KY, Kwon SW, Park SD, et al. Impact of gender on heart failure presentation in non-obstructive hypertrophic cardiomyopathy. Heart and vessels. 2020;35(2):214-22.

23. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):e783-831.

24. Semsarian C, Ho CY. Screening children at risk for hypertrophic cardiomyopathy: balancing benefits and harms. European heart journal. 2019;40(45):3682-4.

25. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation research. 2017;121(7):749-70.

26. Kraft T, Montag J, Radocaj A, Brenner B. Hypertrophic Cardiomyopathy: Cell-to-Cell Imbalance in Gene Expression and Contraction Force as Trigger for Disease Phenotype Development. Circulation research. 2016;119(9):992-5.

27. Hallioglu Kilinc O, Giray D, Bisgin A, Tug Bozdogan S, Karpuz D. Familial hypertrophic cardiomyopathy: A case with a new mutation in the MYBPC3 gene. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir. 2017;45(5):450-3.

28. Tower-Rader A, Desai MY. Phenotype-Genotype Correlation in Hypertrophic Cardiomyopathy: Less Signal, More Noise? Circulation Cardiovascular imaging. 2017;10(2).

29. Weissler-Snir A, Adler A, Williams L, Gruner C, Rakowski H. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. European heart journal. 2017;38(22):1728-37.
30. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517-24.
31. Lee SP, Ashley EA, Homburger J, Caleshu C, Green EM, Jacoby D, et al. Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. Circulation Heart failure. 2018;11(9):e005191.
32. Bongini C, Ferrantini C, Girolami F, Coppini R, Arretini A, Targetti M, et al. Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. The American journal of cardiology. 2016;117(7):1151-9.
33. Viswanathan SK, Sanders HK, McNamara JW, Jagadeesan A, Jahangir A, Tajik AJ, et al. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage. PloS one. 2017;12(11):e0187948.
34. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2008;52(7):559-66.
35. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circulation Heart failure. 2012;5(4):535-46.
36. Ommen SR, Shah PM, Tajik AJ. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart. 2008;94(10):1276-81.
37. Miller RJH, Heidary S, Pavlovic A, Schlachter A, Dash R, Fleischmann D, et al. Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging. PloS one. 2019;14(6):e0217612.
38. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124(1):40-7.
39. Groarke JD, Galazka PZ, Cirino AL, Lakdawala NK, Thune JJ, Bundgaard H, et al. Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. European heart journal cardiovascular Imaging. 2018;19(10):1109-16.

Figures
Figure 1

Echocardiography parameters in MYBPC3 and MYH7 patients (no significant difference was observed in the presented parameters, p>0.05) (Abbreviations: IVS interventricular septum, PLW posterolateral wall, LA left atrium, LVEDV left ventricle end-diastolic volume, LVESV left ventricle end-systolic volume, LVEF left ventricle ejection fraction)